Aficamten Beats Metoprolol in Obstructive HCM, Strengthening Case Ahead of FDA Decision
Cytokinetics’ aficamten improved symptoms and cardiopulmonary performance more than metoprolol in a 175-patient head-to-head study of obstructive hypertrophic cardiomyopathy (oHCM), with detailed data unveiled at the ESC Congress (Madrid).
After 24 weeks, patients on aficamten showed an average +1.1 mL/kg/min increase in peak VO₂, while the metoprolol arm declined. >50% of aficamten patients reported better physical limitation scores vs 26% on metoprolol, alongside improved quality of life. Analysts suggest aficamten could displace beta-blockers as first-line in oHCM. The U.S. FDA is expected to decide by December 2025.
You May Interested In
Glow70/KLOW80 99% China Peptides Warehouse Direct Delivery Lyophilized Powder in Stock
$1.8E+2/UNIT FOB
2026-08-24
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
EU Chemicals Regulatory Update: Practical Compliance Actions Following ECHA January 2026 Developments
-
Aficamten Beats Metoprolol in Obstructive HCM, Strengthening Case Ahead of FDA Decision
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
关于进一步规范化学品信息发布、加强全球管制目录宣导的公告 Announcement on Further Standardizing the Release of Chemical Information and Strengthening Public Awareness of Global Control Lists
-
Canada Issues Non-Compliance Notice to Dr. Reddy’s on Semaglutide Generic
-
South Korea’s Largest Petrochemical Hub Moves to Cut Cracker Capacity by 40%
-
关于将4-amino-1-boc-piperidine、tert-buty 4-aminopiperidine-1-carboxylate产品列入《ECHEMI平台禁限售商品目录》的公告 Announcement on Including 4-amino-1-boc-piperidine and tert-buty 4-aminopiperidine-1-carboxylate in the Announcement on the List of Prohibited Sales of Prohibited and Controlled Items on ECHEMI
-
FDA Fast-Tracks U.S. Drug Manufacturing
-
FDA Warning Letters Put GMP Back in Focus
-
Pesticide Market in Limbo: Prices Plunge Amid Weak Demand and Overcapacity—Only a Few Hold Firm
Recommend Reading
-
![U.S. FDA Opens New Safety Review of RSV Treatments for Infants]()
U.S. FDA Opens New Safety Review of RSV Treatments for Infants
-
![The FDA Officially Blesses AI for Liver Drug Development]()
The FDA Officially Blesses AI for Liver Drug Development
-
![A Fake Email Drains RMB 12 Million: Asia’s Waterproof Giant’s Overseas ‘Payment Heist’ Exposes the Fatal Blind Spot of Chinese Corporate Globalization]()
A Fake Email Drains RMB 12 Million: Asia’s Waterproof Giant’s Overseas ‘Payment Heist’ Exposes the Fatal Blind Spot of Chinese Corporate Globalization
-
![FDA Revokes Orange B Authorization and Proposes Removing Citrus Red No. 2]()
FDA Revokes Orange B Authorization and Proposes Removing Citrus Red No. 2
-
![FDA Dye Tracker Raises Reformulation Pressure Across Food Brands]()
FDA Dye Tracker Raises Reformulation Pressure Across Food Brands
-
![Business Society’s Market Outlook for Natural Rubber on August 10, 2026: Slight Consolidation]()
Business Society’s Market Outlook for Natural Rubber on August 10, 2026: Slight Consolidation
-
![Business Society’s MIBK Market Outlook on August 10, 2026: Stable Operation]()
Business Society’s MIBK Market Outlook on August 10, 2026: Stable Operation
-
![Premium Global Chemical Sourcing Requests (10-12Aug, 2026)]()
Premium Global Chemical Sourcing Requests (10-12Aug, 2026)
-
![Today, PET polyester bottle flakes rebound strongly (12.19)]()
Today, PET polyester bottle flakes rebound strongly (12.19)
-
![Business Society’s Market Outlook for Palm Oil on August 10, 2026: Volatile Rise]()
Business Society’s Market Outlook for Palm Oil on August 10, 2026: Volatile Rise
